Abstract
Purpose
Somatostatin receptor (sstr) positive tumours vary widely in uptake of radiolabelled somatostatin (sst) analogues. This study determinates variability in lesion uptake of the glycosylated sst analogon Nα-(1-deoxy-d-fructosyl)-Nɛ-(2-[18F]fluoropropionyl)-Lys0-Tyr3-octreotate (Gluc-Lys([18F]FP)-TOCA) and correlates it with lesion size and arterial perfusion as measured on computed tomography (CT).
Methods
Ten patients with metastasized neuroendocrine carcinomas were investigated with positron emission tomography PET/CT (Biograph 16, Siemens, Germany). Lesion standardized uptake values (SUVs) were determined at ∼50 min post tracer injection according to a 60% isocontour volume of interest around each lesion. Lesion size and enhancement in the arterial phase (hounsfield units, HUs) were derived from CT.
Results
114 lesions in the upper abdomen had a correlate on both, PET and CT. Variability in lesion SUVs was high (SUVmean 22 ± 13). Intraindividually, there was a sigmoid positive correlation between lesion SUV and lesion diameter indicating partial volume effects. Residual variability in lesions ≥3 cm (≥2.5 cm) ranged down to about half (third) of the maximum lesion uptake and remained unexplained by partial volume effects. No correlation with measured HU in the arterial phase was found, neither intraindividually nor interindividually.
Conclusion
Partial volume effects were a major source of intraindividual variability in tumour tracer uptake. Lesions below 2.5 to 3 cm should thus be used with caution when performing dose calculations. In larger lesions residual variability in uptake must be considered; it may be due to variable sstr2 expression on the tumours’ cell surfaces.
Similar content being viewed by others
References
Meisetschlager G, Poethko T, Stahl A, Wolf I, Scheidhauer K, Schottelius M, et al. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. J Nucl Med 2006;47:566–73.
Schottelius M, Poethko T, Herz M, Reubi JC, Kessler H, Schwaiger M, et al. First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin Cancer Res 2004;10:3593–606.
Wester HJ, Schottelius M, Scheidhauer K, Meisetschlager G, Herz M, Rau FC, et al. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel (18)F-labelled, carbohydrated analogue of octreotide. Eur J Nucl Med Mol Imaging 2003;30:117–22.
Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273–82.
Stahl A, Meisetschlager G, Schottelius M, Bruus-Jensen K, Wolf I, Scheidhauer K, et al. [(123)I]Mtr-TOCA, a radioiodinated and carbohydrated analogue of octreotide: scintigraphic comparison with [(111)In]octreotide. Eur J Nucl Med Mol Imaging 2006;33:45–52.
Wester HJ, Schottelius M, Scheidhauer K, Reubi JC, Wolf I, Schwaiger M. Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics. Eur J Nucl Med Mol Imaging 2002;29:28–38.
Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34:982–93.
Koenig JA, Kaur R, Dodgeon I, Edwardson JM, Humphrey PP. Fates of endocytosed somatostatin sst2 receptors and associated agonists. Biochem J 1998;336 (Pt 2):291–98.
Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003;30:207–16.
Cremonesi M, Ferrari M, Zoboli S, Chinol M, Stabin MG, Orsi F, et al. Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC. Eur J Nucl Med 1999;26:877–86.
Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, De Jong M. Peptide receptor radionuclide therapy. Ann N Y Acad Sci 2004;1014:234–45.
Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001;12:941–45.
Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002;43:610–6.
Cremonesi M, Ferrari M, Chinol M, Bartolomei M, Stabin MG, Sacco E, et al. Dosimetry in radionuclide therapies with 90Y-conjugates: the IEO experience. Q J Nucl Med 2000;44:325–32.
Brix G, Bellemann ME, Hauser H, Doll J. [Recovery coefficients for the quantification of the arterial input functions from dynamic PET measurements: experimental and theoretical determination]. Nuklearmedizin 2002;41:184–90.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wieder, H., Beer, A.J., Poethko, T. et al. PET/CT with Gluc-Lys-([18F]FP)-TOCA: correlation between uptake, size and arterial perfusion in somatostatin receptor positive lesions. Eur J Nucl Med Mol Imaging 35, 264–271 (2008). https://doi.org/10.1007/s00259-007-0576-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-007-0576-1